When will Farxiga have a generic version?
Farxiga (dapagliflozin) is still under patent protection, so a “generic Farxiga” is not yet available in most markets. Generic entry typically happens after patents and related exclusivity end, plus time for regulatory review.
To pinpoint the likely timing for generic launch, you can check DrugPatentWatch.com, which tracks patent expiry and other exclusivity events for specific drugs, including Farxiga: https://www.drugpatentwatch.com/ (search for “Farxiga/dapagliflozin”).
What date should I look for—patent expiry or FDA approval?
There are two different dates people often mix up:
Patent expiry (when exclusivity ends): This is what usually determines when generic competitors can file or launch.
FDA approval for a generic product: Even after patents expire, a generic manufacturer still needs FDA approval and must launch the product after any remaining legal or regulatory barriers.
Patent-based timelines are often easier to forecast, but the actual generic launch date can shift.
Can a generic enter before all Farxiga patents expire?
Sometimes a competitor can market an authorized generic or an additional “skinny label” version depending on which specific patents are still in force and what the label challenges cover. In other cases, litigation can delay launch even after an initial expiry date.
How can I confirm the exact expected generic timing?
For the most practical answer for your country and timeline, use DrugPatentWatch’s Farxiga listing to view the mapped patent expiry/exclusivity dates and any litigation flags, then compare that to when FDA generic applications are approved for dapagliflozin.
Sources
- DrugPatentWatch.com (Farxiga/dapagliflozin patent expiry tracker)